Susquehanna International Group LLP Grows Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Susquehanna International Group LLP increased its holdings in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 269.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 374,845 shares of the company’s stock after acquiring an additional 273,395 shares during the period. Susquehanna International Group LLP’s holdings in DiaMedica Therapeutics were worth $2,035,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new stake in DiaMedica Therapeutics in the fourth quarter valued at approximately $81,000. Raymond James Financial Inc. purchased a new position in DiaMedica Therapeutics during the fourth quarter valued at $83,000. Bank of Montreal Can purchased a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $84,000. Dimensional Fund Advisors LP raised its position in shares of DiaMedica Therapeutics by 14.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company’s stock worth $105,000 after purchasing an additional 2,380 shares during the last quarter. Finally, World Investment Advisors acquired a new stake in DiaMedica Therapeutics in the 4th quarter worth about $119,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their price target on DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 19th.

DiaMedica Therapeutics Price Performance

DMAC opened at $3.76 on Friday. The firm has a market capitalization of $161.14 million, a price-to-earnings ratio of -6.71 and a beta of 1.29. The company’s 50 day simple moving average is $4.31 and its two-hundred day simple moving average is $5.00. DiaMedica Therapeutics Inc. has a 1-year low of $2.14 and a 1-year high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, equities analysts anticipate that DiaMedica Therapeutics Inc. will post -0.59 earnings per share for the current fiscal year.

DiaMedica Therapeutics Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.